

Digital applications for on-body devices discussed at Wearable Injectors and Connected Devices conference 2021

SMi Group reports: The latest innovations in digital health and on-body drug delivery for the pharmaceutical industry

LONDON, ENGLAND, UNITED KINGDOM, August 31, 2021 /EINPresswire.com/ -- The upcoming conference in October will consider key developments in the wearable injectors field, including the enhanced demand for on-body injectors and digitalised health as the pandemic highlights the



need for self-administered at-home care, managing sustainability in the field, and opportunities for development in <u>oncology</u>.

You can view the two-day agenda and speaker programme on the event website: www.wearable-injectors.co.uk/pr5EINNEWS

Overcoming the Divide Between Telemedicine and Clinic with High-fidelity Data and Low Impact Devices

- •Contemporary medicine has become increasingly reliant on cutting edge tools and treatments which are built out within large medical centers requiring patients to come to the care they need
- •This care model is not adequate for those whom are disadvantaged by traditional health disparities, those whom are aging in place and, evidenced by the global pandemic, those whom we need to reduce the probability of acquiring a communicable disease
- •The National Cancer Institute and, more broadly, the U.S. National Institutes of Health have been developing and funding initiatives aimed at moving the needle towards bringing care-topatient
- •This session will focus on these efforts and the strategy behind them for the future of remote patient monitoring

Christopher Hartshorn, Program Director, Division of Cancer Treatment and Diagnosis, National Cancer Institute of the U.S. National Institutes of Health

Digital Product Development - Connecting the team as well as the device

- •Case Study: Illustrating how the development process for digital medical devices requires effective collaboration across a wide range of technical disciplines
- •The challenges that this can present
- •Strategies to address these challenges Chris Hurlstone, Director of Engineering, Team Consulting

Wearable injectors and digital applications

- •How to reconcile the areas drug development, medical device and advanced digital applications
- •Development, LCM and regulatory strategy, from data collection to medical devices Norbert Lauber, Head Autoinjector & Large Volume Delivery Systems, Novartis

Register online: www.wearable-injectors.co.uk/pr5EINNEWS
Proudly sponsored by: Quantex-arc and Avery Dennison Medical

--- ENDS ---

Contact Information:

For media enquiries contact Jinna Sidhu on Tel: +44 (0)20 7827 6088 / Email:

hsidhu@smi-online.co.uk

About **SMi Group**:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses, and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Jinna Sidhu SMi Group +44 20 7827 6088 email us here

This press release can be viewed online at: https://www.einpresswire.com/article/550179334

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.